In the present study, combined therapy consisting of gefitinib and fulvestrant led to enhanced anti-proliferative activity in EGFR-mutant lung cancer cells and improved PFS in adenocarcinoma patient with an EGFR mutation. Here, EGFR is linked to lung carcinoma.